Prosperity Consulting Group LLC Takes $1.03 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Prosperity Consulting Group LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,926 shares of the biotechnology company's stock, valued at approximately $1,032,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the 4th quarter worth approximately $25,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after buying an additional 58 shares in the last quarter. Natixis purchased a new position in United Therapeutics in the 4th quarter valued at $85,000. Finally, Anchor Investment Management LLC lifted its holdings in United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of UTHR traded up $2.33 during trading hours on Wednesday, hitting $303.09. The stock had a trading volume of 784,302 shares, compared to its average volume of 448,872. The firm has a market cap of $13.61 billion, a P/E ratio of 13.31, a P/E/G ratio of 0.97 and a beta of 0.63. The company's fifty day simple moving average is $305.66 and its 200 day simple moving average is $345.68. United Therapeutics Co. has a 12-month low of $236.65 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the company posted $6.17 earnings per share. The firm's revenue was up 17.2% compared to the same quarter last year. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $911,330.28. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 74,500 shares of company stock valued at $24,472,050. 11.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. cut their target price on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a research note on Monday, April 21st. Finally, UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $390.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.